

Conforms to Regulation (EC) No. 1907/2006 (REACH), Annex II, as amended by UK REACH Regulation SI 2019/758

SAFETY DATA SHEET

SIMPLY REFRESH MULTISURFACE EGGSHELL POLISHED PEBBLE

SECTION 1: Identification of the substance/mixture and of the company/ undertaking

1.1 Product identifier

Product name

: SIMPLY REFRESH MULTISURFACE EGGSHELL POLISHED PEBBLE

1.2 Relevant identified uses of the substance or mixture and uses advised against

	Identified uses	
Professional use Consumer use		
	Uses advised against	
None		

Product use

: Waterborne coating for interior use.

1.3 Details of the supplier of the safety data sheet

ICI Paints AkzoNobel, Wexham Road, Slough, Berkshire, SL2 5DS, U.K. Tel.: +44 (0) 333 222 71 71 www.dulux.co.uk e-mail address of person : dulux.advice@akzonobel.com responsible for this SDS

1.4 Emergency telephone number

National advisory body/Poison Center

Telephone number	: +44 (0)344 892 0111
<u>Supplier</u>	
Telephone number	: Emergency Telephone : Slough +44 (0) 1753 550000

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture				
Product definition	: Mixture			
Classification according to Not classified.	o Regulation (EC) No. 1272/2008 [CLP/GHS]			
The product is not classified	as hazardous according to Regulation (EC) 1272/2008 as amended.			
See Section 11 for more deta	tailed information on health effects and symptoms.			

2.2 Label elements

Signal word	: No signal word.		
Date of issue/Date of revision	: 27-1-2024	Version : 1	
Date of previous issue	: No previous validation	1/15	AkzoNobel

SECTION 2: Hazards	ic	lentification
Hazard statements	:	No known significant effects or critical hazards.
Precautionary statements		
General	:	P102 - Keep out of reach of children. P101 - If medical advice is needed, have product container or label at hand.
Prevention	:	P262 - Do not get in eyes, on skin, or on clothing.
Response	:	P312 - Call a doctor if you feel unwell.
Storage	:	Not applicable.
Disposal	:	P501 - Dispose of contents and container in accordance with all local, regional, national and international regulations.
Supplemental label elements	:	Contains 2,4,7,9-tetramethyldec-5-yne-4,7-diol, 1,2-benzisothiazol-3(2H)-one and CMIT/MIT(3:1). May produce an allergic reaction. Warning! Hazardous respirable droplets may be formed when sprayed. Do not breathe spray or mist.
Annex XVII - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles	:	
Special packaging requirem	en	<u>ts</u>
Containers to be fitted with child-resistant fastenings	:	Not applicable.
Tactile warning of danger	:	Not applicable.
2.3 Other hazards		
Product meets the criteria for PBT or vPvB according to Regulation (EC) No. 1907/2006, Annex XIII	:	This mixture does not contain any substances that are assessed to be a PBT or a vPvB.
Other hazards which do not result in classification	:	None known.
SECTION 3: Compos	iti	on/information on ingradiants

SECTION 3: Composition/information on ingredients

3.2 Mixtures	: Mixture				
Product/ingredient name	Identifiers	%	Classification	Specific Conc. Limits, M-factors and ATEs	Туре
titanium dioxide	REACH #: 01-2119489379-17 EC: 236-675-5 CAS: 13463-67-7	≥20 - ≤25	Carc. 2, H351 (inhalation)	-	[1] [*]
2,4,7,9-tetramethyldec- 5-yne-4,7-diol	REACH #: 01-2119954390-39 EC: 204-809-1 CAS: 126-86-3	<1	Eye Dam. 1, H318 Skin Sens. 1B, H317 Aquatic Chronic 3, H412	-	[1]
1,2-benzisothiazol-3(2H)- one	EC: 220-120-9 CAS: 2634-33-5	<0.05	Acute Tox. 4, H302 Acute Tox. 2, H330 Skin Irrit. 2, H315 Eye Dam. 1, H318 Skin Sens. 1, H317 Aquatic Acute 1, H400 Aquatic Chronic 2,	ATE [Oral] = 500 mg/kg ATE [Inhalation (dusts and mists)] = 0.05 mg/l Skin Sens. 1, H317: C $\geq 0.05\%$	[1]
Date of issue/Date of revision	: 27-1-2024		Version :1	-	
Date of previous issue	: No previous valida	ation	2/15	Akzol	Nobe

SECTION 3: Composition/information on ingredients					
			H411	M [Acute] = 10	
CMIT/MIT(3:1)	REACH #: 01-2120764691-48 EC: 911-418-6 CAS: 55965-84-9 Index: 613-167-00-5	<0.0015	Acute Tox. 3, H301 Acute Tox. 2, H310 Acute Tox. 2, H330 Skin Corr. 1C, H314 Eye Dam. 1, H318 Skin Sens. 1A, H317 Aquatic Acute 1, H400 Aquatic Chronic 1, H410 EUH071	ATE [Oral] = 100 mg/kg ATE [Dermal] = 50 mg/kg ATE [Inhalation (dusts and mists)] = 0.05 mg/l Skin Corr. 1C, H314: C \geq 0.6% Skin Irrit. 2, H315: 0.06% \leq C < 0.6% Eye Dam. 1, H318: C \geq 0.6% Eye Irrit. 2, H319: 0.06% \leq C < 0.6% Skin Sens. 1, H317: C \geq 0.0015% M [Acute] = 100 M [Chronic] = 100	[1]
			See Section 16 for the full text of the H statements declared above.		

There are no additional ingredients present which, within the current knowledge of the supplier and in the concentrations applicable, are classified as hazardous to health or the environment, are PBTs, vPvBs or Substances of equivalent concern, or have been assigned a workplace exposure limit and hence require reporting in this section. <u>Type</u>

[1] Substance classified with a physical, health or environmental hazard

[*] The classification as a carcinogen by inhalation applies only to mixtures placed on the market in powder form containing 1% or more of titanium dioxide particles with aerodynamic diameter \leq 10 µm not bound within a matrix.

Occupational exposure limits, if available, are listed in Section 8.

SECTION 4: First aid measures

4.1 Description of first aid measures

Eye contact	: Immediately flush eyes with plenty of water, occasionally lifting the upper and lower eyelids. Check for and remove any contact lenses if easy to do. Get medical attention if irritation occurs.
Inhalation	: Remove victim to fresh air and keep at rest in a position comfortable for breathing. Get medical attention if symptoms occur.
Skin contact	: Flush contaminated skin with plenty of water. Remove contaminated clothing and shoes. Get medical attention if symptoms occur.
Ingestion	: Wash out mouth with water. If material has been swallowed and the exposed person is conscious, give small quantities of water to drink. Do not induce vomiting unless directed to do so by medical personnel. Get medical attention if symptoms occur.
Protection of first-aiders	: No action shall be taken involving any personal risk or without suitable training.

4.2 Most important symptoms and effects, both acute and delayed



Conforms to Regulation (EC) No. 1907/2006 (REACH), Annex II, as amended by UK REACH Regulation SI 2019/758

SIMPLY REFRESH MULTISURFACE EGGSHELL POLISHED PEBBLE

SECTION 4: First aid measures

There are no data available on the mixture itself. The mixture has been assessed following the conventional method of the CLP Regulation (EC) No 1272/2008 and is classified for toxicological properties accordingly. See Sections 2 and 3 for details.

Exposure to component solvent vapor concentrations in excess of the stated occupational exposure limit may result in adverse health effects such as mucous membrane and respiratory system irritation and adverse effects on the kidneys, liver and central nervous system. Symptoms and signs include headache, dizziness, fatigue, muscular weakness, drowsiness and, in extreme cases, loss of consciousness.

Solvents may cause some of the above effects by absorption through the skin. Repeated or prolonged contact with the mixture may cause removal of natural fat from the skin, resulting in non-allergic contact dermatitis and absorption through the skin.

If splashed in the eyes, the liquid may cause irritation and reversible damage.

This takes into account, where known, delayed and immediate effects and also chronic effects of components from short-term and long-term exposure by oral, inhalation and dermal routes of exposure and eye contact.

Contains 2,4,7,9-tetramethyldec-5-yne-4,7-diol, 1,2-benzisothiazol-3(2H)-one, CMIT/MIT(3:1). May produce an allergic reaction.

Over-exposure signs/symptoms

Eye contact	: No specific data.
Inhalation	: No specific data.
Skin contact	: No specific data.
Ingestion	: No specific data.

4.3 Indication of any immediate medical attention and special treatment needed

Notes to physician	 Treat symptomatically. Contact poison treatment specialist immediately if large quantities have been ingested or inhaled.
Specific treatments	: No specific treatment.

SECTION 5: Firefighting measures

_		-		
5.1 Extinguishing media				
Suitable extinguishing media	:	Use an extinguishing agent	suitable for the surrounding fir	e.
Unsuitable extinguishing media	:	None known.		
5.2 Special hazards arising f	ror	n the substance or mixture		
Hazards from the substance or mixture	:	In a fire or if heated, a press	ure increase will occur and the	e container may burst.
Hazardous combustion products	:	Decomposition products ma carbon dioxide carbon monoxide sulfur oxides metal oxide/oxides	y include the following materia	als:
5.3 Advice for firefighters				
Special protective actions for fire-fighters	:		by removing all persons from the all be taken involving any perso	
Special protective equipment for fire-fighters	:	breathing apparatus (SCBA mode. Clothing for fire-fight	propriate protective equipmen) with a full face-piece operate ers (including helmets, protect ndard EN 469 will provide a ba	d in positive pressure tive boots and gloves)
Date of issue/Date of revision		: 27-1-2024	Version : 1	
Date of previous issue		: No previous validation	4/15	AkzoNobel

SECTION 6: Accidental release measures

6.1 Personal precautions, pro	ective equipment and emergency procedures
For non-emergency personnel	: No action shall be taken involving any personal risk or without suitable training. Evacuate surrounding areas. Keep unnecessary and unprotected personnel from entering. Do not touch or walk through spilled material. Put on appropriate personal protective equipment.
For emergency responders	: If specialized clothing is required to deal with the spillage, take note of any information in Section 8 on suitable and unsuitable materials. See also the information in "For non-emergency personnel".
6.2 Environmental precautions	: Avoid dispersal of spilled material and runoff and contact with soil, waterways, drains and sewers. Inform the relevant authorities if the product has caused environmental pollution (sewers, waterways, soil or air).
6.3 Methods and materials for	containment and cleaning up
Small spill	: Stop leak if without risk. Move containers from spill area. Dilute with water and mop up if water-soluble. Alternatively, or if water-insoluble, absorb with an inert dry material and place in an appropriate waste disposal container. Dispose of via a licensed waste disposal contractor.
Large spill	: Stop leak if without risk. Move containers from spill area. Prevent entry into sewers, water courses, basements or confined areas. Wash spillages into an effluent treatment plant or proceed as follows. Contain and collect spillage with non-combustible, absorbent material e.g. sand, earth, vermiculite or diatomaceous earth and place in container for disposal according to local regulations. Dispose of via a licensed waste disposal contractor.
6.4 Reference to other sections	: See Section 1 for emergency contact information. See Section 8 for information on appropriate personal protective equipment. See Section 13 for additional waste treatment information.

SECTION 7: Handling and storage

The information in this section contains generic advice and guidance.

7.1 Precautions for safe handling

Protective measures	: Put on appropriate personal protective equipment (see Section 8).
Advice on general occupational hygiene	: Eating, drinking and smoking should be prohibited in areas where this material is handled, stored and processed. Workers should wash hands and face before eating, drinking and smoking. Remove contaminated clothing and protective equipment before entering eating areas. See also Section 8 for additional information on hygiene measures.

7.2 Conditions for safe storage, including any incompatibilities

Store in accordance with local regulations. Store in original container protected from direct sunlight in a dry, cool and well-ventilated area, away from incompatible materials (see Section 10) and food and drink. Keep container tightly closed and sealed until ready for use. Containers that have been opened must be carefully resealed and kept upright to prevent leakage. Do not store in unlabeled containers. Use appropriate containment to avoid environmental contamination. See Section 10 for incompatible materials before handling or use.

7.3 Specific end use(s)	
Recommendations	: Not available.
Industrial sector specific	: Not available.
solutions	



SECTION 8: Exposure controls/personal protection

The information in this section contains generic advice and guidance. Information is provided based on typical anticipated uses of the product. Additional measures might be required for bulk handling or other uses that could significantly increase worker exposure or environmental releases.

8.1 Control parameters

Occupational exposure limits

No exposure limit value known.	
Recommended monitoring : procedures	If this product contains ingredients with exposure limits, personal, workplace atmosphere or biological monitoring may be required to determine the effectiveness of the ventilation or other control measures and/or the necessity to use respiratory protective equipment. Reference should be made to monitoring standards, such as the following: European Standard EN 689 (Workplace atmospheres - Guidance for the assessment of exposure by inhalation to chemical agents for comparison with limit values and measurement strategy) European Standard EN 14042 (Workplace atmospheres - Guide for the application and use of procedures for the assessment of exposure to chemical and biological agents) European Standard EN 482 (Workplace atmospheres - General requirements for the performance of procedures for the measurement of chemical agents) Reference to national guidance documents for methods for the determination of hazardous substances will also be required.

DNELs/DMELs

2,4,7,9-tetramethyldec-5-yne-4,7-diol DNEL Long term Oral 0.25 mg/ kg bw/day General population Systemic DNEL Long term Dermal 0.43 mg/m³ General gopulation Systemic DNEL Long term Dermal 0.43 mg/m³ General gopulation Systemic DNEL Long term Dermal 0.5 mg/ gbw/day Workers Systemic DNEL Long term Dermal 0.5 mg/ bw/day Workers Systemic DNEL Short term Oral 0.75 mg/ gbw/day General population Systemic DNEL Short term Dermal 0.75 mg/ kg bw/day General population Systemic DNEL Short term Dermal 1.5 mg/kg bw/day Workers Systemic DNEL Short term Dermal 1.5 mg/kg bw/day Workers Systemic DNEL Long term 1.76 mg/m³ Workers Systemic 1,2-benzisothiazol-3(2H)-one DNEL Long term Dermal 0.345 mg/ bw/day Workers Systemic DNEL Long term Dreg term 6eneral population Systemic DNEL Long term 0.20 mg/m³ General population<	redient name
NELLong term Dermalkg bw/day 0.25 mg/ kg bw/daypopulation General populationSystemicDNELLong term Inhalation0.43 mg/mGeneral populationSystemicDNELLong term Dermal0.5 mg/kg bw/dayWorkersSystemicDNELShort term Oral0.75 mg/ kg bw/dayGeneral populationSystemicDNELShort term Dermal0.75 mg/ kg bw/dayGeneral populationSystemicDNELShort term Dermal0.75 mg/ kg bw/dayGeneral populationSystemicDNELShort term Dermal1.29 mg/mGeneral populationSystemicDNELShort term Dermal1.76 mg/kg bw/dayWorkersSystemicDNELShort term Dermal1.76 mg/mWorkersSystemicDNELLong term Dermal0.345 mg/ kg bw/dayWorkersSystemic1,2-benzisothiazol-3(2H)-oneDNELLong term Dermal0.345 mg/ kg bw/daySystemic1,2-benzisothiazol-3(2H)-oneDNELLong term Inhalation0.345 mg/ kg bw/dayGeneral systemicSystemic1,2-benzisothiazol-3(2H)-oneDNELLong term Inhalation0.345 mg/ kg bw/dayGeneral systemicSystemic1,2-benzisothiazol-3(2H)-oneDNELLong term Inhalation0.24 mg/m³General systemicSystemic1,2-benzisothiazol-3(2H)-oneDNELLong term Inhalation0.24 mg/m³General systemicSystemicDNELLong term Inhalation <t< td=""><td>dec-5-yne-4,7-diol</td></t<>	dec-5-yne-4,7-diol
DNELLong term Dermal inhalation0.25 mg/ kg bw/dayGeneral opulationSystemicDNELLong term inhalation0.43 mg/m³General opulationSystemicDNELLong term Dermal0.5 mg/kg bw/dayWorkersSystemicDNELShort term Oral0.75 mg/ kg bw/dayGeneral opulationSystemicDNELShort term Oral0.75 mg/ kg bw/dayGeneral opulationSystemicDNELShort term Dermal0.75 mg/ kg bw/dayGeneral opulationSystemicDNELShort term Inhalation1.29 mg/m³ bw/dayGeneral opulationSystemicDNELShort term Inhalation1.5 mg/kg bw/dayWorkersSystemicDNELShort term Inhalation1.76 mg/m³ bw/dayWorkersSystemic1,2-benzisothiazol-3(2H)-oneDNELLong term Dermal Inhalation0.345 mg/ bw/dayGeneral populationSystemic1,2-benzisothiazol-3(2H)-oneDNELLong term Dermal Inhalation0.345 mg/ bw/dayGeneral populationSystemic1,2-benzisothiazol-3(2H)-oneDNELLong term Dermal Inhalation0.345 mg/ bw/dayGeneral populationSystemic1,2-benzisothiazol-3(2H)-oneDNELLong term Dermal Inhalation0.345 mg/ bw/dayGeneral populationSystemic1,2-benzisothiazol-3(2H)-oneDNELLong term Inhalation0.02 mg/m³General populationSystemic1,2-benzisothiazol-3(2H)-oneDNELLon	
Vkg bw/day populationpopulation General populationDNELLong term Inhalation0.43 mg/m³General populationSystemicDNELLong term Dermal0.5 mg/kg bw/dayWorkersSystemicDNELShort term Oral0.75 mg/ kg bw/dayGeneral populationSystemicDNELShort term Dermal0.75 mg/ kg bw/dayGeneral populationSystemicDNELShort term Dermal0.75 mg/ kg bw/dayGeneral populationSystemicDNELShort term Dermal1.29 mg/m³General populationSystemicDNELShort term Dermal1.5 mg/kg bw/dayWorkersSystemicDNELLong term1.76 mg/m³ bw/dayWorkersSystemicDNELLong term0.345 mg/ kg bw/dayGeneral populationSystemic1,2-benzisothiazol-3(2H)-oneDNELLong term Dermal0.345 mg/ bw/dayGeneral populationSystemic1,2-benzisothiazol-3(2H)-oneDNELLong term Dermal0.345 mg/ bw/dayGeneral populationSystemic1,2-benzisothiazol-3(2H)-oneDNELLong term Dermal0.345 mg/ bw/dayGeneral populationSystemic1,2-benzisothiazol-3(2H)-oneDNELLong term Inhalation0.02 mg/m³General populationSystemic1,2-benzisothiazol-3(2H)-oneDNELLong term Inhalation0.02 mg/m³General populationSystemic0NELLong term Inhalation0.02 mg/m³General<	1
DNEL InhalationLong term Inhalation0.43 mg/m³ populationGeneral populationSystemicDNEL DNELCong term Dermal0.5 mg/kg 0.75 mg/ kg bw/dayWorkersSystemicDNEL Short term Oral0.75 mg/ 0.75 mg/ general populationGeneral populationSystemicDNEL DNELShort term Dermal0.75 mg/ 0.75 mg/ general populationSystemic systemic populationSystemicDNEL InhalationShort term Inhalation1.29 mg/m³ General populationGeneral systemic populationSystemicDNEL InhalationShort term Inhalation1.5 mg/kg bw/dayWorkersSystemicDNEL DNEL DNELCong term Inhalation1.76 mg/m³ WorkersGeneral systemic bw/daySystemic1,2-benzisothiazol-3(2H)-oneDNEL DNEL Long term Dermal0.345 mg/ 0.345 mg/ workersGeneral Systemic inhalationSystemic systemic mopulationSystemic systemic mopulation1,2-benzisothiazol-3(2H)-oneDNEL DNEL Long term Dermal0.345 mg/ 0.345 mg/ workersGeneral Systemic systemic mopulationSystemic systemic systemic mopulation1,2-benzisothiazol-3(2H)-oneDNEL DNEL Long term DNEL Long term0.345 mg/ DownGeneral systemic systemic systemic mopulationSystemic systemic systemic mopulation1,2-benzisothiazol-3(2H)-oneDNEL DNEL Long termLong term term0.345 mg/ systemic systemic systemic systemic systemic	
Inhalation Long term Dermalpopulation Workerspopulation Systemic bw/dayDNELShort term Oral0.5 mg/kg bw/dayWorkersSystemic Systemic populationDNELShort term Dermal0.75 mg/ kg bw/dayGeneral opopulationSystemic Systemic mopulationDNELShort term Dermal0.75 mg/ kg bw/dayGeneral opopulationSystemic systemicDNELShort term Dermal1.29 mg/m³General systemicSystemicDNELShort term Dermal1.5 mg/kg bw/dayWorkersSystemicDNELShort term Dermal1.5 mg/kg bw/dayWorkersSystemicDNELLong term Inhalation1.76 mg/m³ bw/dayWorkersSystemic1,2-benzisothiazol-3(2H)-oneDNELLong term Dermal Inhalation0.345 mg/ bw/dayGeneral populationSystemic byopulation1,2-benzisothiazol-3(2H)-oneDNELLong term Dermal Inhalation0.345 mg/ bw/dayGeneral populationSystemic byopulation1,2-benzisothiazol-3(2H)-oneDNELLong term Dermal Inhalation0.345 mg/ bw/dayGeneral populationSystemic byopulation1,2-benzisothiazol-3(2H)-oneDNELLong term Inhalation0.20 mg/m³ populationGeneral populationSystemic Long term1,2-benzisothiazol-3(2H)-oneDNELLong term Inhalation0.20 mg/m³ populationGeneral populationSystemic LocalCMIT/MIT(3:1)DNELLong term Inhalation0.02 mg	1
DNELLong term Dermal0.5 mg/kg bw/dayWorkersSystemicDNELShort term Oral0.75 mg/ kg bw/dayGeneral populationSystemicDNELShort term Dermal0.75 mg/ kg bw/dayGeneral populationSystemicDNELShort term Dermal0.75 mg/ kg bw/dayGeneral populationSystemicDNELShort term1.29 mg/m³General generalSystemicDNELShort term Dermal1.5 mg/kg bw/dayWorkersSystemicDNELShort term Dermal1.76 mg/m³WorkersSystemicDNELLong term1.76 mg/m³WorkersSystemicDNELShort term5.28 mg/m³WorkersSystemicInhalationDNELLong term Dermal0.345 mg/ kg bw/dayGeneral populationSystemic1,2-benzisothiazol-3(2H)-oneDNELLong term Dermal0.345 mg/ kg bw/dayGeneral populationSystemic1,2-benzisothiazol-3(2H)-oneDNELLong term0.966 mg/ kg bw/dayGeneral populationSystemic1,2-benzisothiazol-3(2H)-oneDNELLong term0.02 mg/m³General populationSystemic1,2-benzisothiazol-3(2H)-oneDNELLong term0.02 mg/m³General populationSystemicDNELLong term0.02 mg/m³General populationSystemicSystemicDNELLong term0.02 mg/m³General populationLocal populationLocal populationLocal population <td></td>	
bw/daybw/dayDNELShort term Oral0.75 mg/ (g bw/dayGeneral (population)Systemic (g bw/day)DNELShort term Dermal0.75 mg/ (g bw/day)General (population)Systemic (g bw/day)DNELShort term1.29 mg/m³General (population)Systemic (g bw/day)DNELShort term1.5 mg/kg (bw/day)WorkersSystemic (population)DNELShort term Dermal1.5 mg/kg (bw/day)WorkersSystemic (population)DNELLong term1.76 mg/m³ (bw/day)WorkersSystemic (bw/day)DNELLong term1.76 mg/m³ (bw/day)WorkersSystemic (bw/day)1,2-benzisothiazol-3(2H)-oneDNELLong term0.345 mg/ (g bw/day)General (g bw/day)Systemic (g bw/day)1,2-benzisothiazol-3(2H)-oneDNELLong term Dermal (Inhalation)0.345 mg/ (g General)Systemic (g bw/day)1,2-benzisothiazol-3(2H)-oneDNELLong term (Inhalation)0.345 mg/ (g General)Systemic (g bw/day)DNELLong term (Inhalation)0.966 mg/ (lnhalation)WorkersSystemic (g bw/day)DNELLong term (Inhalation)0.02 mg/m³General (population)Systemic (g bw/day)CMIT/MIT(3:1)DNELLong term (Inhalation)0.02 mg/m³General (population)Local (D cal)DNELShort term (Inhalation)0.04 mg/m³General (D cal)Local (D cal)DNELShort term	
DNELShort term Oral0.75 mg/ kg bw/day 0.75 mg/ kg bw/day 0.75 mg/ kg bw/day 0.75 mg/ general opulationSystemic systemic populationDNELShort term Dermal0.75 mg/ kg bw/day 0.75 mg/ kg bw/day 0.29 mg/m3General gopulationSystemic systemic populationDNELShort term Inhalation1.29 mg/m3 bw/dayGeneral populationSystemic populationDNELShort term Dermal Inhalation1.5 mg/kg bw/dayWorkersSystemic systemic population1,2-benzisothiazol-3(2H)-oneDNELLong term Inhalation5.28 mg/m3 bw/dayWorkersSystemic systemic hg bw/day1,2-benzisothiazol-3(2H)-oneDNELLong term Dermal Inhalation0.345 mg/ kg bw/dayGeneral populationSystemic systemic kg bw/day1,2-benzisothiazol-3(2H)-oneDNELLong term Dermal Inhalation0.345 mg/ kg bw/dayGeneral populationSystemic systemic kg bw/day1,2-benzisothiazol-3(2H)-oneDNELLong term Dermal Inhalation0.345 mg/ kg bw/dayGeneral populationSystemic systemic population1,2-benzisothiazol-3(2H)-oneDNELLong term Inhalation0.20 mg/m3General populationSystemic systemic population1,2-benzisothiazol-3(2H)-oneDNELLong term Inhalation0.02 mg/m3General populationSystemic systemic population0.MIT/MIT(3:1)DNELLong term Inhalation0.02 mg/m3General populationLocal population </td <td></td>	
Langle ConstructionKig bw/day DNELpopulation Systemic populationSystemic populationDNELShort term Inhalation1.29 mg/m³General populationSystemic populationDNELShort term Dermal Inhalation1.5 mg/kg bw/dayWorkersSystemic populationDNELShort term Dermal Inhalation1.5 mg/kg bw/dayWorkersSystemic systemic1,2-benzisothiazol-3(2H)-oneDNELLong term Dermal Inhalation0.345 mg/ bw/dayGeneral populationSystemic systemic inhalation1,2-benzisothiazol-3(2H)-oneDNELLong term Dermal Inhalation0.345 mg/ bw/dayGeneral populationSystemic systemic population1,2-benzisothiazol-3(2H)-oneDNELLong term Dermal Inhalation0.345 mg/ bw/dayGeneral populationSystemic population1,2-benzisothiazol-3(2H)-oneDNELLong term Dermal Inhalation0.345 mg/ by WorkersSystemic population1,2-benzisothiazol-3(2H)-oneDNELLong term Dermal Inhalation0.345 mg/ by WorkersSystemic population1,2-benzisothiazol-3(2H)-oneDNELLong term Inhalation0.966 mg/ by WorkersSystemic population0NELLong term Inhalation0.02 mg/m³General populationSystemic populationCMIT/MIT(3:1)DNELLong term Inhalation0.02 mg/m³General populationLocal populationDNELShort term Inhalation0.04 mg/m³General population	r
DNELShort term Dermal0.75 mg/ kg bw/dayGeneral populationSystemicDNELShort term1.29 mg/m³General populationSystemicDNELShort term Dermal1.5 mg/kg bw/dayWorkersSystemicDNELShort term Dermal1.5 mg/kg bw/dayWorkersSystemicDNELLong term1.76 mg/m³WorkersSystemicInhalationDNELShort term5.28 mg/m³WorkersSystemicInhalationDNELLong term Dermal0.345 mg/ kg bw/dayGeneral populationSystemic1,2-benzisothiazol-3(2H)-oneDNELLong term Dermal0.345 mg/ kg bw/dayGeneral populationSystemic1,2-benzisothiazol-3(2H)-oneDNELLong term Dermal0.345 mg/ kg bw/dayGeneral populationSystemic1,2-benzisothiazol-3(2H)-oneDNELLong term Dermal0.345 mg/ kg bw/dayGeneral populationSystemic0NELLong term0.20 gf/m³General populationSystemicSystemic0NELLong term0.02 mg/m³General populationSystemicCMIT/MIT(3:1)DNELLong term0.02 mg/m³General populationLocal populationDNELLong term0.02 mg/m³General populationLocalDNELShort term0.04 mg/m³General populationLocalDNELShort term0.04 mg/m³KorkersLocal	ľ
Langle ConstructionKg bw/day populationpopulation General populationSystemicDNELShort term Inhalation1.29 mg/m³General populationSystemicDNELShort term Dermal1.5 mg/kg bw/dayWorkersSystemicDNELLong term Inhalation1.76 mg/m³WorkersSystemicDNELShort term5.28 mg/m³WorkersSystemic1,2-benzisothiazol-3(2H)-oneDNELLong term Dermal Inhalation0.345 mg/ kg bw/dayGeneral populationSystemic1,2-benzisothiazol-3(2H)-oneDNELLong term Dermal Inhalation0.345 mg/ NELGeneral populationSystemic1,2-benzisothiazol-3(2H)-oneDNELLong term Dermal Inhalation0.345 mg/ NCELGeneral populationSystemic1,2-benzisothiazol-3(2H)-oneDNELLong term Dermal Inhalation0.345 mg/ NCELGeneral populationSystemic0NELLong term0.966 mg/ kg bw/dayWorkersSystemicDNELLong term6.81 mg/m³General populationSystemicCMIT/MIT(3:1)DNELLong term0.02 mg/m³General populationLocal populationDNELLong term0.02 mg/m³General populationLocal populationDNELShort term0.04 mg/m³General populationLocal	
DNELShort term Inhalation1.29 mg/m³General populationSystemicDNELShort term Dermal1.5 mg/kg bw/dayWorkersSystemicDNELLong term Inhalation1.76 mg/m³WorkersSystemicDNELLong term Inhalation5.28 mg/m³WorkersSystemic1,2-benzisothiazol-3(2H)-oneDNELLong term Dermal Inhalation0.345 mg/ gbw/dayGeneral populationSystemic1,2-benzisothiazol-3(2H)-oneDNELLong term Dermal Inhalation0.966 mg/ kg bw/dayWorkersSystemicDNELLong term Dermal0.966 mg/ kg bw/dayGeneral populationSystemicDNELLong term Inhalation1.2 mg/m³General populationSystemicDNELLong term Inhalation0.02 mg/m³General populationSystemicCMIT/MIT(3:1)DNELLong term Inhalation0.02 mg/m³General populationLocal populationDNELLong term Inhalation0.02 mg/m³General populationLocal populationLocalDNELLong term Inhalation0.04 mg/m³General populationLocalDNELShort term Inhalation0.04 mg/m³General populationLocal	1
InhalationpopulationDNELShort term Dermal1.5 mg/kg bw/dayWorkersSystemicDNELLong term1.76 mg/m³WorkersSystemicInhalationDNELShort term5.28 mg/m³WorkersSystemic1,2-benzisothiazol-3(2H)-oneDNELLong term Dermal0.345 mg/ kg bw/dayGeneral populationSystemic1,2-benzisothiazol-3(2H)-oneDNELLong term Dermal0.345 mg/ kg bw/dayGeneral populationSystemicDNELLong term Dermal0.966 mg/ kg bw/dayWorkersSystemic lnhalationSystemic kg bw/daySystemicDNELLong term Inhalation1.2 mg/m³General gopulationSystemic populationSystemic populationSystemic populationCMIT/MIT(3:1)DNELLong term Inhalation0.02 mg/m³General populationLocal populationLocal populationDNELLong term Inhalation0.02 mg/m³General populationLocal populationLocalDNELLong term Inhalation0.04 mg/m³General populationLocalDNELShort term0.04 mg/m³General populationLocal	
DNELShort term Dermal1.5 mg/kg bw/dayWorkersSystemicDNELLong term Inhalation1.76 mg/m³WorkersSystemic1,2-benzisothiazol-3(2H)-oneDNELShort term Inhalation5.28 mg/m³WorkersSystemic1,2-benzisothiazol-3(2H)-oneDNELLong term Dermal0.345 mg/ kg bw/dayGeneralSystemicDNELLong term Dermal0.345 mg/ kg bw/dayGeneralSystemicDNELLong term Dermal0.966 mg/ kg bw/dayWorkersSystemicDNELLong term Dermal1.2 mg/m³General populationSystemicDNELLong term Inhalation6.81 mg/m³WorkersSystemicCMIT/MIT(3:1)DNELLong term Inhalation0.02 mg/m³General populationSystemicDNELLong term Inhalation0.02 mg/m³General populationLocal populationLocalDNELShort term Inhalation0.04 mg/m³General populationLocal	1
bw/daybw/dayDNELLong term1.76 mg/m³WorkersSystemic1,2-benzisothiazol-3(2H)-oneDNELShort term5.28 mg/m³WorkersSystemic1,2-benzisothiazol-3(2H)-oneDNELLong term Dermal0.345 mg/ kg bw/dayGeneralSystemicDNELLong term Dermal0.966 mg/ kg bw/dayWorkersSystemicDNELLong term Dermal1.2 mg/m³GeneralSystemicDNELLong term1.2 mg/m³GeneralSystemicDNELLong term6.81 mg/m³WorkersSystemicDNELLong term0.02 mg/m³GeneralLocalDNELLong term0.02 mg/m³GeneralLocalDNELLong term0.02 mg/m³GeneralLocalDNELLong term0.02 mg/m³WorkersLocalDNELLong term0.04 mg/m³GeneralLocalDNELShort term0.04 mg/m³WorkersLocal	
InhalationInhalationJob State1,2-benzisothiazol-3(2H)-oneDNELShort term Inhalation5.28 mg/m³WorkersSystemic1,2-benzisothiazol-3(2H)-oneDNELLong term Dermal0.345 mg/ kg bw/dayGeneral populationSystemicDNELLong term Dermal0.966 mg/ kg bw/dayWorkersSystemicDNELLong term Dermal0.966 mg/ kg bw/dayWorkersSystemicDNELLong term Inhalation1.2 mg/m³General populationSystemicDNELLong term Inhalation6.81 mg/m³WorkersSystemicDNELLong term Inhalation0.02 mg/m³General populationLocal populationDNELLong term Inhalation0.02 mg/m³General populationLocal populationDNELShort term Inhalation0.04 mg/m³General populationLocal	Ľ
DNELShort term Inhalation5.28 mg/m³WorkersSystemic1,2-benzisothiazol-3(2H)-oneDNELLong term Dermal0.345 mg/ kg bw/dayGeneral populationSystemicDNELLong term Dermal0.966 mg/ kg bw/dayWorkersSystemicDNELLong term Dermal1.2 mg/m³General populationSystemicDNELLong term Inhalation1.2 mg/m³General populationSystemicDNELLong term Inhalation0.02 mg/m³General populationSystemicCMIT/MIT(3:1)DNELLong term Inhalation0.02 mg/m³General populationLocal populationDNELLong term Inhalation0.02 mg/m³General populationLocal populationDNELShort term Inhalation0.04 mg/m³General populationLocal	[
InhalationDNELInhalationSecond Second Secon	
1,2-benzisothiazol-3(2H)-oneDNELLong term Dermal0.345 mg/ kg bw/dayGeneral populationSystemicDNELLong term Dermal0.966 mg/ kg bw/dayWorkersSystemicDNELLong term1.2 mg/m³General populationSystemicDNELLong term6.81 mg/m³WorkersSystemicDNELLong term6.81 mg/m³WorkersSystemicDNELLong term0.02 mg/m³General populationSystemicCMIT/MIT(3:1)DNELLong term0.02 mg/m³General populationLocalDNELLong term0.02 mg/m³General populationLocalDNELShort term0.04 mg/m³General populationLocal	[
DNELLong term Dermalkg bw/day 0.966 mg/ kg bw/daypopulationSystemicDNELLong term Inhalation1.2 mg/m³General populationSystemicDNELLong term Inhalation6.81 mg/m³WorkersSystemicDNELLong term Inhalation6.81 mg/m³WorkersSystemicCMIT/MIT(3:1)DNELLong term Inhalation0.02 mg/m³General populationLocal populationDNELLong term Inhalation0.02 mg/m³General populationLocal populationDNELLong term Inhalation0.02 mg/m³General populationLocal populationDNELShort term Inhalation0.04 mg/m³General populationLocalDNELShort term Inhalation0.04 mg/m³General populationLocal	
DNELLong term Dermal0.966 mg/ kg bw/dayWorkersSystemicDNELLong term1.2 mg/m³General populationSystemicDNELLong term6.81 mg/m³WorkersSystemicDNELLong term6.81 mg/m³WorkersSystemicCMIT/MIT(3:1)DNELLong term0.02 mg/m³General populationLocalDNELLong term0.02 mg/m³General populationLocalDNELLong term0.02 mg/m³General populationLocalDNELShort term0.04 mg/m³General populationLocalDNELShort term0.04 mg/m³General populationLocal	-3(2H)-one
CMIT/MIT(3:1)DNELLong term Inhalationkg bw/day 1.2 mg/m³General populationSystemicCMIT/MIT(3:1)DNELLong term Inhalation6.81 mg/m³WorkersSystemicDNELLong term Inhalation0.02 mg/m³General populationLocal populationDNELLong term Inhalation0.02 mg/m³General populationLocal populationDNELLong term Inhalation0.02 mg/m³General populationLocal populationDNELShort term Inhalation0.04 mg/m³General populationLocalDNELShort term Inhalation0.04 mg/m³General populationLocal	
DNELLong term Inhalation1.2 mg/m³General populationSystemicDNELLong term Inhalation6.81 mg/m³WorkersSystemicCMIT/MIT(3:1)DNELLong term Inhalation0.02 mg/m³General populationLocalDNELLong term Inhalation0.02 mg/m³WorkersLocalDNELLong term Inhalation0.02 mg/m³WorkersLocalDNELShort term Inhalation0.04 mg/m³General populationLocalDNELShort term Inhalation0.04 mg/m³General populationLocal]
CMIT/MIT(3:1)Inhalation Long term Inhalationpopulation WorkersSystemicCMIT/MIT(3:1)DNELLong term Inhalation0.02 mg/m³General populationLocal populationDNELLong term Inhalation0.02 mg/m³General populationLocal populationDNELLong term Inhalation0.02 mg/m³General populationLocal populationDNELShort term Inhalation0.04 mg/m³General populationLocalDNELShort term Inhalation0.04 mg/m³General populationLocal	
CMIT/MIT(3:1)Inhalation Long term Inhalationpopulation WorkersSystemicCMIT/MIT(3:1)DNELLong term Inhalation0.02 mg/m³General populationLocal DNELDNELLong term Inhalation0.02 mg/m³General populationLocal LocalDNELLong term Inhalation0.02 mg/m³General populationLocalDNELShort term Inhalation0.04 mg/m³General populationLocalDNELShort term Inhalation0.04 mg/m³General populationLocal	[
CMIT/MIT(3:1)DNELLong term Inhalation6.81 mg/m³WorkersSystemicCMIT/MIT(3:1)DNELLong term Inhalation0.02 mg/m³General populationLocal populationDNELLong term Inhalation0.02 mg/m³WorkersLocal populationDNELShort term Inhalation0.04 mg/m³General populationLocal populationDNELShort term Inhalation0.04 mg/m³General populationLocal population	
CMIT/MIT(3:1)InhalationInhalation0.02 mg/m³General populationLocalDNELLong term0.02 mg/m³WorkersLocalInhalationDNELLong term0.02 mg/m³WorkersLocalDNELShort term0.04 mg/m³General populationLocalDNELShort term0.04 mg/m³General populationLocalDNELShort term0.04 mg/m³General populationLocal	1
InhalationpopulationDNELLong term0.02 mg/m³WorkersLocalInhalationDNELShort term0.04 mg/m³GeneralLocalInhalationDNELShort term0.04 mg/m³GeneralLocalDNELShort term0.04 mg/m³WorkersLocal	
InhalationpopulationDNELLong term0.02 mg/m³WorkersLocalInhalationDNELShort term0.04 mg/m³GeneralLocalInhalationDNELShort term0.04 mg/m³GeneralLocalDNELShort term0.04 mg/m³WorkersLocal	1
DNELLong term Inhalation0.02 mg/m³WorkersLocalDNELShort term Inhalation0.04 mg/m³General populationLocalDNELShort term0.04 mg/m³WorkersLocal	
InhalationInhalationInhalationLocalDNELShort term0.04 mg/m³GeneralLocalInhalationpopulationDNELShort term0.04 mg/m³WorkersLocal	1
DNELShort term Inhalation0.04 mg/m³General populationLocalDNELShort term0.04 mg/m³WorkersLocal	
InhalationpopulationDNELShort term0.04 mg/m³WorkersLocal	1
DNEL Short term 0.04 mg/m³ Workers Local	
	1
e of issue/Date of revision : 27-1-2024 Version : 1	ision : 07.1.0
e of previous issue : No previous validation 6/15 AKZOI	: No pre



	SIMPLY R	EFRESH M	ULTISURFACE EGGSHE	ELL POLISHED I	PEBBLE				
SECTION 8: Exposu	re con	trols/p	ersonal prote	ction					
		DNEL DNEL	Long term Oral Short term Oral	0.09 mg/ kg bw/day 0.11 mg/ kg bw/day	General population General population	Systemic Systemic			
<u>PNECs</u> No PNECs available.									
8.2 Exposure controls									
Appropriate engineering controls		: Good general ventilation should be sufficient to control worker exposure to airborne contaminants.							
Individual protection meas	ures								
Hygiene measures	: Wash hands, forearms and face thoroughly after handling chemical products, before eating, smoking and using the lavatory and at the end of the working period. Appropriate techniques should be used to remove potentially contaminated clothing. Wash contaminated clothing before reusing. Ensure that eyewash stations and safety showers are close to the workstation location.								
Eye/face protection	asse gase unle	: Safety eyewear complying with an approved standard should be used when a risk assessment indicates this is necessary to avoid exposure to liquid splashes, mists, gases or dusts. If contact is possible, the following protection should be worn, unless the assessment indicates a higher degree of protection: safety glasses with side-shields.							
Skin protection									
Hand protection	be w this Whe prote reco Whe (bre Rec	vorn at all is necess en prolon ection cla mmende en only br akthroug ommend ves shoul	I times when handlin sary. ged or frequently rep iss of 6 (breakthroug d. Recommended g ief contact is expect h time >30 minutes a ed gloves: Nitrile, thi	g chemical pro- peated contact th time >480 ploves: Viton (ed, a glove w according to E ckness ≥ 0.12	roducts if a risk a et may occur, a g minutes accordin ® or Nitrile, thick ith protection cla EN374) is recom 2 mm.	ng to EN374) is ness ≥ 0.38 mm. ass of 2 or higher			
			ance or effectiveness nage and poor maint		may be reduced	d by physical/			
	proc	luct is the	st check that the fina most appropriate and ded in the user's risk	nd takes into	account the part	cted for handling this ticular conditions of			
Body protection	bein	Personal protective equipment for the body should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product.							
Other skin protection	sele	Appropriate footwear and any additional skin protection measures should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product.							
Respiratory protection	appi resp aspe Dry and/ expo resp	opriate s iratory pr ects of us sanding or hazard osure car iratory pr	e. , flame cutting and/o	on. Respirato ensure prope r welding of t nding/flatting the provision of should be use	ors must be used or fitting, training he dry paint film should be used f local exhaust v	d according to a , and other important will give rise to dust wherever possible. If ventilation, suitable			

SECTION 8: Exposure controls/personal protection

Environmental exposure	: Emissions from ventilation or work process equipment should be checked to
controls	ensure they comply with the requirements of environmental protection legislation.
	In some cases, fume scrubbers, filters or engineering modifications to the process
	equipment will be necessary to reduce emissions to acceptable levels.

SECTION 9: Physical and chemical properties

The conditions of measurement of all properties are at standard temperature and pressure unless otherwise indicated.

9.1 Information on basic physical and chemical properties

<u>Appearance</u>	
Physical state	: Liquid.
Color	: White.
Odor	: Characteristic.
Odor threshold	: Not available.
Melting point/freezing point	: Not available.
Boiling point, initial boiling point, and boiling range	: 100°C (212°F)
Flammability	: Not available.
Lower and upper explosion limit	: Not available.
Flash point	: Not available.
Auto-ignition temperature	:

Ingredient name	°C	°F	Method
DPG-DME	165	329	
2-(2-ethoxyethoxy)ethanol	204	399.2	
2-dimethylaminoethanol	230	446	DIN 51794

Decomposition temperature	:	Not available.
рН	:	7.5 [Conc. (% w/w): 100%] [DIN EN 1262]
Viscosity	:	Kinematic (room temperature): 1224 mm²/s [DIN EN ISO 3219] Kinematic (40°C): Not applicable. [DIN EN ISO 3219]
Solubility(ies)	:	

Solubility(ies)

Media	Result
cold water	Soluble [OESO (TG 105)]

Partition coefficient: n-octanol/ : Not applicable.

1

water

Vapor pressure

	V	Vapor Pressure at 20°C			Vapor pressure at 50°C		
Ingredient name	mm Hg	kPa	Method	mm Hg	kPa	Method	
ammonia	360.03	48					
triethylamine	54	7.2					
ethanol	42.95	5.7					
Relative density	: 1.3)7	-+		·	·	
Vapor density	: Not	available.					
Particle characteristics							
Median particle size	: Not	applicable.					
to of icous/Data of revision	. 77 1 9	004		Varaian 1			

Date of issue/Date of revision	: 27-1-2024	Version :1	
Date of previous issue	: No previous validation	8/15	AkzoNobel

SECTION 9: Physical and chemical properties

Percentage of particles with : 0 aerodynamic diameter ≤ 10 µm

SECTION 10: Stability and reactivity		
10.1 Reactivity	: No specific test data related to reactivity available for this product or its ingredients.	
10.2 Chemical stability	: The product is stable.	
10.3 Possibility of hazardous reactions	: Under normal conditions of storage and use, hazardous reactions will not occur.	
10.4 Conditions to avoid	: No specific data.	
10.5 Incompatible materials	: No specific data.	
10.6 Hazardous decomposition products	: Under normal conditions of storage and use, hazardous decomposition products should not be produced.	

SECTION 11: Toxicological information

11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008

There are no data available on the mixture itself. The mixture has been assessed following the conventional method of the CLP Regulation (EC) No 1272/2008 and is classified for toxicological properties accordingly. See Sections 2 and 3 for details.

Exposure to component solvent vapor concentrations in excess of the stated occupational exposure limit may result in adverse health effects such as mucous membrane and respiratory system irritation and adverse effects on the kidneys, liver and central nervous system. Symptoms and signs include headache, dizziness, fatigue, muscular weakness, drowsiness and, in extreme cases, loss of consciousness.

Solvents may cause some of the above effects by absorption through the skin. Repeated or prolonged contact with the mixture may cause removal of natural fat from the skin, resulting in non-allergic contact dermatitis and absorption through the skin.

If splashed in the eyes, the liquid may cause irritation and reversible damage.

This takes into account, where known, delayed and immediate effects and also chronic effects of components from short-term and long-term exposure by oral, inhalation and dermal routes of exposure and eye contact.

Contains 2,4,7,9-tetramethyldec-5-yne-4,7-diol, 1,2-benzisothiazol-3(2H)-one, CMIT/MIT(3:1). May produce an allergic reaction.

Acute toxicity

Product/ingredient name	Result	Species	Dose	Exposure
1,2-benzisothiazol-3(2H)- one	LD50 Oral	Mouse	1150 mg/kg	-
	LD50 Oral	Rat	1020 mg/kg	-

Conclusion/Summary : Not available.

Acute toxicity estimates



SECTION 11: Toxicological information

Product/ingredient name	Oral (mg/ kg)	Dermal (mg/kg)	Inhalation (gases) (ppm)	Inhalation (vapors) (mg/l)	Inhalation (dusts and mists) (mg/l)
Product as-supplied	N/A	N/A	N/A	1996.7	N/A
1,2-benzisothiazol-3(2H)-one	500	N/A	N/A	N/A	0.05
CMIT/MIT(3:1)	100	50	N/A	N/A	0.05

Irritation/Corrosion

Product/ingredient name	Result	Species	Score	Exposure	Observation
2,4,7,9-tetramethyldec-	Eyes - Severe irritant	Rabbit	-	0.1 MI	-
5-yne-4,7-diol	Skin - Mild irritant	Rabbit	_	0.5 gm	_
Conclusion/Summary	: Not available.	T CODAC		0.0 gm	
Sensitization	. NUL AVAIIADIE.				
	: Not available.				
Conclusion/Summary	. NUL AVAIIADIE.				
Mutagenicity	: Not available.				
Conclusion/Summary	i not avallable.				
Carcinogenicity	. Net evelleble				
Conclusion/Summary	: Not available.				
Reproductive toxicity	- NI - 6 11 - 11				
Conclusion/Summary	: Not available.				
<u>Teratogenicity</u>	.				
Conclusion/Summary	: Not available.				
Specific target organ toxici	<u>ty (single exposure)</u>				
Not available.					
<u>Specific target organ toxici</u>	<u>ty (repeated exposure)</u>				
Not available.					
Aspiration hazard					
Not available.					
nformation on the likely	: Not available.				
outes of exposure					
otential acute health effects	<u>s</u>				
	NI. 1		rds.		
Eye contact	: No known significant ef	ects or critical naza			
Eye contact Inhalation	: No known significant ef				
•	e e	fects or critical haza	rds.		
Inhalation	: No known significant ef	fects or critical haza fects or critical haza	rds. rds.		
Inhalation Skin contact	: No known significant ef : No known significant ef	fects or critical haza fects or critical haza	rds. rds.		
Inhalation Skin contact Ingestion	 No known significant ef No known significant ef No known significant ef 	fects or critical haza fects or critical haza fects or critical haza	rds. rds. rds.		
Inhalation Skin contact	 No known significant ef No known significant ef No known significant ef 	fects or critical haza fects or critical haza fects or critical haza	rds. rds. rds.		
Inhalation Skin contact Ingestion symptoms related to the phy	 No known significant ef No known significant ef No known significant ef No known significant ef 	fects or critical haza fects or critical haza fects or critical haza	rds. rds. rds.		
Inhalation Skin contact Ingestion <u>symptoms related to the phy</u> Eye contact	 No known significant ef No known significant ef No known significant ef No known significant ef 	fects or critical haza fects or critical haza fects or critical haza	rds. rds. rds.		

Delayed and immediate effects and also chronic effects from short and long term exposure Short term exposure

Date of issue/Date of revision	: 27-1-2024	Version : 1	
Date of previous issue	: No previous validation	10/15	AkzoNobel

SECTION 11: Toxicological information

Potential immediate effects	: Not available.
Potential delayed effects	: Not available.
Long term exposure	
Potential immediate effects	: Not available.
Potential delayed effects	: Not available.
Potential chronic health effe	ects
Not available.	
Conclusion/Summary	: Not available.
General	: No known significant effects or critical hazards.
Carcinogenicity	: No known significant effects or critical hazards.
Mutagenicity	: No known significant effects or critical hazards.
Reproductive toxicity	: No known significant effects or critical hazards.

11.2 Information on other hazards

11.2.1 Endocrine disrupting properties

Not available.

11.2.2 Other information

No additional information.

SECTION 12: Ecological information

12.1 Toxicity

There are no data available on the mixture itself. Do not allow to enter drains or watercourses.

The mixture has been assessed following the summation method of the CLP Regulation (EC) No 1272/2008 and is not classified as hazardous to the environment, but contains substance(s) hazardous to the environment. See section 3 for details.

Product/ingredient name	Result	Species	Exposure
titanium dioxide	Acute LC50 >1000 mg/l Fresh water	Fish - Pimephales promelas	96 hours
1,2-benzisothiazol-3(2H)-one	Acute EC50 97 ppb Fresh water	Daphnia - Daphnia magna	48 hours
	Acute EC50 2.24 ppm Fresh water	Daphnia - Daphnia magna	48 hours
	Acute EC50 3.7 ppm Fresh water	Daphnia - Daphnia magna	48 hours
	Acute EC50 1.1 ppm Fresh water	Daphnia - Daphnia magna	48 hours
	Acute EC50 2 ppm Fresh water	Daphnia - Daphnia magna	48 hours
	Acute LC50 10 to 20 mg/l Fresh water	Crustaceans - Ceriodaphnia	48 hours
		dubia	
	Acute LC50 540 ppb Fresh water	Fish - Lepomis macrochirus	96 hours
	Acute LC50 167 ppb Fresh water	Fish - Oncorhynchus mykiss	96 hours
	Acute LC50 0.75 ppm Fresh water	Fish - Oncorhynchus mykiss	96 hours
	Acute LC50 1.8 ppm Fresh water	Fish - Oncorhynchus mykiss	96 hours
	Acute LC50 1.6 ppm Fresh water	Fish - Oncorhynchus mykiss	96 hours

Conclusion/Summary : Not available.

12.2 Persistence and degradability

Conclusion/Summary : Not available.

12.3 Bioaccumulative potential

Not available.

Date of issue/Date of revision Date of previous issue



SECTION 12: Ecological information

12.4 Mobility in soil

Soil/water partition coefficient (Koc)	: Not available.
Mobility	: Not available.

12.5 Results of PBT and vPvB assessment

This mixture does not contain any substances that are assessed to be a PBT or a vPvB.

12.6 Endocrine disrupting properties

Not available.

12.7 Other adverse effects

No known significant effects or critical hazards.

SECTION 13: Disposal considerations

The information in this section contains generic advice and guidance. The list of Identified Uses in Section 1 should be consulted for any available use-specific information provided in the Exposure Scenario(s).

13.1 Waste treatment methods

<u>Product</u>	
Methods of disposal	: The generation of waste should be avoided or minimized wherever possible. Disposal of this product, solutions and any by-products should at all times comply with the requirements of environmental protection and waste disposal legislation and any regional local authority requirements. Dispose of surplus and non-recyclable products via a licensed waste disposal contractor. Waste should not be disposed of untreated to the sewer unless fully compliant with the requirements of all authorities with jurisdiction.
Hazardous waste	: Within the present knowledge of the supplier, this product is not regarded as hazardous waste, as defined by EU Directive 2008/98/EC.
Disposal considerations	 Do not allow to enter drains or watercourses. Dispose of according to all federal, state and local applicable regulations. If this product is mixed with other wastes, the original waste product code may no longer apply and the appropriate code should be assigned. For further information, contact your local waste authority.

European waste catalogue (EWC)

The European Waste Catalogue classification of this product, when disposed of as waste, is:

Waste code	Waste designation		
EWC 08 01 12	waste paint and varnish other than those mentioned in 08 01 11		
Packaging			
Methods of disposal	: The generation of waste shou packaging should be recycled when recycling is not feasible	. Incineration or landfill shou	•
Disposal considerations	 Using information provided in this safety data sheet, advice should be obtained from the relevant waste authority on the classification of empty containers. Empty containers must be scrapped or reconditioned. Dispose of containers contaminated by the product in accordance with local or national legal provisions. 		
Special precautions	: This material and its container must be disposed of in a safe way. Empty contain or liners may retain some product residues. Avoid dispersal of spilled material a runoff and contact with soil, waterways, drains and sewers.		al of spilled material and
ate of issue/Date of revision	: 27-1-2024	Version :1	
ate of previous issue	: No previous validation	12/15	AkzoNobel

SECTION 14: Transport information

	ADR/RID	IMDG	
14.1 UN number or ID number	Not regulated.	Not regulated.	
14.2 UN proper shipping name	-		
14.3 Transport hazard class(es)	-	-	
14.4 Packing group	-	-	
14.5 Environmental hazards	No.	No.	

14.6 Special precautions for user: **Transport within user's premises:** always transport in closed containers that are upright and secure. Ensure that persons transporting the product know what to do in the event of an accident or spillage.

14.7 Transport in bulk: Not applicable.according to IMOinstruments

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

UK (GB) /REACH

Annex XIV - List of substances subject to authorization

Annex XIV

None of the components are listed.

Substances of very high concern

None of the components are listed.

Annex XVII - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles	: Not applicable.
Other EU regulations	
VOC	: The provisions of Directive 2004/42/EC on VOC apply to this product. Refer to the product label and/or technical data sheet for further information.
VOC for Ready-for-Use Mixture	: Not available.
Industrial emissions (integrated pollution prevention and control) - Air	: Not listed



Conforms to Regulation (EC) No. 1907/2006 (REACH), Annex II, as amended by UK REACH Regulation SI 2019/758

SIMPLY REFRESH MULTISURFACE EGGSHELL POLISHED PEBBLE

SECTION 15: Regulatory information

Industrial emissions : Not listed (integrated pollution prevention and control) -Water Ozone depleting substances (1005/2009/EU) Not listed. Prior Informed Consent (PIC) (649/2012/EU) Not listed. Persistent Organic Pollutants Not listed. **Seveso Directive** This product is not controlled under the Seveso Directive. **Biocidal products regulation** International regulations Chemical Weapon Convention List Schedules I, II & III Chemicals Not listed. **Montreal Protocol** Not listed. **Stockholm Convention on Persistent Organic Pollutants** Not listed. Rotterdam Convention on Prior Informed Consent (PIC) Not listed. **UNECE Aarhus Protocol on POPs and Heavy Metals** Not listed.

15.2 Chemical Safety : No Chemical Safety Assessment has been carried out.

Assessment

SECTION 16: Other information

Indicates information that has changed from previously issued version.

Abbreviations and	: ATE = Acute Toxicity Estimate
acronyms	CLP = Classification, Labelling and Packaging Regulation [Regulation (EC) No.
-	1272/2008]
	DMEL = Derived Minimal Effect Level
	DNEL = Derived No Effect Level
	EUH statement = CLP-specific Hazard statement
	N/A = Not available
	PBT = Persistent, Bioaccumulative and Toxic
	PNEC = Predicted No Effect Concentration
	RRN = REACH Registration Number
	SGG = Segregation Group
	vPvB = Very Persistent and Very Bioaccumulative

Procedure used to derive the classification according to Regulation (EC) No. 1272/2008 [CLP/GHS]

Classification	Justification
Not classified.	

Full text of abbreviated H statements

Date of issue/Date of revision	: 27-1-2024	Version : 1	
Date of previous issue	: No previous validation	14/15	AkzoNobel

SECTION 16: Other	' information
H301 H302 H310 H314 H315 H317 H318 H330 H351 H400 H410 H411 H412 EUH071	Toxic if swallowed. Harmful if swallowed. Fatal in contact with skin. Causes severe skin burns and eye damage. Causes skin irritation. May cause an allergic skin reaction. Causes serious eye damage. Fatal if inhaled. Suspected of causing cancer. Very toxic to aquatic life. Very toxic to aquatic life. Very toxic to aquatic life with long lasting effects. Toxic to aquatic life with long lasting effects. Harmful to aquatic life with long lasting effects. Corrosive to the respiratory tract.
Full text of classifications	
Acute Tox. 2 Acute Tox. 3 Acute Tox. 4 Aquatic Acute 1 Aquatic Chronic 1 Aquatic Chronic 2 Aquatic Chronic 3 Carc. 2 Eye Dam. 1 Skin Corr. 1C Skin Irrit. 2 Skin Sens. 1 Skin Sens. 1A	ACUTE TOXICITY - Category 2 ACUTE TOXICITY - Category 3 ACUTE TOXICITY - Category 4 AQUATIC HAZARD (ACUTE) - Category 1 AQUATIC HAZARD (LONG-TERM) - Category 1 AQUATIC HAZARD (LONG-TERM) - Category 2 AQUATIC HAZARD (LONG-TERM) - Category 3 CARCINOGENICITY - Category 2 SERIOUS EYE DAMAGE/ EYE IRRITATION - Category 1 SKIN CORROSION/IRRITATION - Category 1C SKIN CORROSION/IRRITATION - Category 2 SKIN SENSITIZATION - Category 1 SKIN SENSITIZATION - Category 1 SKIN SENSITIZATION - Category 1
Date of printing Date of issue/ Date of revision Date of previous issue Version Unique ID <u>Notice to reader</u>	 27-1-2024 27-1-2024 No previous validation 1 DA7DF488320C1EEEAF920FFCE5EF83B5

